期刊
BLOOD REVIEWS
卷 29, 期 3, 页码 179-189出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2014.10.006
关键词
Antiplatelet agents; Arterial thrombosis; Platelets; Protease-activated receptors; Thrombin
类别
资金
- National Health and Medical Research Council of Australia
- CASS Foundation
Twenty-three years after the discovery of the first thrombin receptor, now known as protease-activated receptor 1 (PAR1), the first drug targeting this receptor is available for human use. The PAR1 inhibitor, vorapaxar (Zontivity, MSD), was recently approved by the FDA for use in the USA for the prevention of thrombotic cardiovascular events in patients with a history of myocardial infarction or peripheral artery disease. In this review, we detail the rationale, development, as well as the clinical significance and considerations of vorapaxar, the original PAR antagonist and the latest anti-platelet agent in the pharmaco-armoury against arterial thrombosis. (C) 2014 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据